Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Waters ( (WAT) ).
On February 9, 2026, Waters completed its previously announced Reverse Morris Trust combination with BD’s Biosciences & Diagnostic Solutions businesses, creating a larger life sciences and diagnostics group with Waters shareholders owning 60.8% and BD shareholders 39.2% of the combined company. The deal, financed in part through a $4.0 billion SpinCo term loan guaranteed by Waters and its key subsidiaries, is designed to strengthen the company’s position in high-volume, regulated testing markets and expand into high-growth adjacent segments.
Following the closing, Waters reorganized into four divisions—Analytical Sciences, Biosciences, Advanced Diagnostics, and Materials Sciences—aligning product lines from chromatography and mass spectrometry to flow cytometry and specialty diagnostics under a unified structure. In parallel, the company put in place tax, employee, intellectual property and transition service agreements with BD and SpinCo, while adding genomics expert Claire M. Fraser to its expanded 11-member board to help oversee integration and future growth.
The most recent analyst rating on (WAT) stock is a Buy with a $440.00 price target. To see the full list of analyst forecasts on Waters stock, see the WAT Stock Forecast page.
Spark’s Take on WAT Stock
According to Spark, TipRanks’ AI Analyst, WAT is a Outperform.
The score is driven by strong earnings-call momentum (beat-and-raise with strong segment performance) and solid underlying financial profitability, supported by a constructive long-term technical trend. These positives are tempered by a relatively high P/E valuation and some cash-flow softness.
To see Spark’s full report on WAT stock, click here.
More about Waters
Waters Corporation is a global life sciences and diagnostics company focused on regulated, high-volume testing environments across pharmaceuticals, food and environmental safety, and clinical diagnostics. Its portfolio spans analytical technologies, informatics, and services, leveraging expertise in chemistry, physics, and biology to support drug development, materials characterization, and earlier disease detection.
Average Trading Volume: 543,296
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.7B
Find detailed analytics on WAT stock on TipRanks’ Stock Analysis page.